Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2022-11-14
- Target Recruit Count
- 130
- Registration Number
- NCT05613478
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
- Conditions
- Interventions
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Fujian Medical University
- Target Recruit Count
- 216
- Registration Number
- NCT05610332
- Locations
- 🇨🇳
Department of Gastric Surgery, Fuzhou, Fujian, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2023-09-28
- Target Recruit Count
- 29
- Registration Number
- NCT05602935
- Locations
- 🇨🇳
The Second Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05600998
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 716
- Registration Number
- NCT05582499
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT05583383
- Locations
- 🇨🇳
Henan Tumor Hospital, Henan, China
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
- Conditions
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 116
- Registration Number
- NCT05559008
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT05547737
Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
- Conditions
- Interventions
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Fujian Medical University
- Target Recruit Count
- 203
- Registration Number
- NCT05524974
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 41
- Registration Number
- NCT05524168
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.